NO20074404L - Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid - Google Patents
Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acidInfo
- Publication number
- NO20074404L NO20074404L NO20074404A NO20074404A NO20074404L NO 20074404 L NO20074404 L NO 20074404L NO 20074404 A NO20074404 A NO 20074404A NO 20074404 A NO20074404 A NO 20074404A NO 20074404 L NO20074404 L NO 20074404L
- Authority
- NO
- Norway
- Prior art keywords
- microcrystalline
- quinolin
- indol
- ylmethyl
- fluoro
- Prior art date
Links
- FATGTHLOZSXOBC-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1CC1=CC=C(C=CC=C2)C2=N1 FATGTHLOZSXOBC-UHFFFAOYSA-N 0.000 title 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0504150.4A GB0504150D0 (en) | 2005-03-01 | 2005-03-01 | Microcrystalline material |
| PCT/GB2006/000704 WO2006092579A1 (en) | 2005-03-01 | 2006-03-01 | Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20074404L true NO20074404L (no) | 2007-10-25 |
Family
ID=34430394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20074404A NO20074404L (no) | 2005-03-01 | 2007-08-29 | Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100041699A1 (pt) |
| EP (1) | EP1856094A1 (pt) |
| JP (1) | JP2008531668A (pt) |
| KR (1) | KR20070107184A (pt) |
| CN (1) | CN101133047A (pt) |
| AU (1) | AU2006219689A1 (pt) |
| BR (1) | BRPI0607423A2 (pt) |
| CA (1) | CA2600891A1 (pt) |
| GB (1) | GB0504150D0 (pt) |
| IL (1) | IL185453A0 (pt) |
| MX (1) | MX2007010588A (pt) |
| NO (1) | NO20074404L (pt) |
| NZ (1) | NZ561246A (pt) |
| RU (1) | RU2007132203A (pt) |
| WO (1) | WO2006092579A1 (pt) |
| ZA (1) | ZA200707233B (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| CA2658496A1 (en) | 2006-07-22 | 2008-01-31 | Oxagen Limited | 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity |
| ATE530523T1 (de) | 2006-08-07 | 2011-11-15 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate |
| WO2009061730A2 (en) | 2007-11-05 | 2009-05-14 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid |
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| CA2712017C (en) | 2008-01-18 | 2016-08-09 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| US8470594B2 (en) * | 2008-04-15 | 2013-06-25 | President And Fellows Of Harvard College | Methods for identifying agents that affect the survival of motor neurons |
| US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| JP5069804B2 (ja) * | 2010-03-01 | 2012-11-07 | 隆雄 篠澤 | 筋萎縮性側索硬化症（ａｌｓ）の患者の進行度を判定し進行のモニターを行う方法 |
| AR080703A1 (es) | 2010-03-22 | 2012-05-02 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| DK2697223T3 (en) | 2011-04-14 | 2016-09-05 | Actelion Pharmaceuticals Ltd | 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| PE20161177A1 (es) | 2014-03-17 | 2016-11-18 | Actelion Pharmaceuticals Ltd | Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2 |
| WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| KR20180053345A (ko) | 2015-09-15 | 2018-05-21 | 이도르시아 파마슈티컬스 리미티드 | 결정질 형태 |
| EP3902795A1 (en) | 2018-12-27 | 2021-11-03 | Chiesi Farmaceutici S.p.A. | Pharmaceutical composition comprising spherical agglomerates of timapiprant |
| CN113975272A (zh) * | 2021-11-29 | 2022-01-28 | 西安交通大学 | 吲哚乙酸（iaa）在制备预防或治疗炎症性肠病药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
-
2005
- 2005-03-01 GB GBGB0504150.4A patent/GB0504150D0/en not_active Ceased
-
2006
- 2006-03-01 NZ NZ561246A patent/NZ561246A/en unknown
- 2006-03-01 US US11/817,399 patent/US20100041699A1/en not_active Abandoned
- 2006-03-01 MX MX2007010588A patent/MX2007010588A/es not_active Application Discontinuation
- 2006-03-01 CA CA002600891A patent/CA2600891A1/en not_active Abandoned
- 2006-03-01 CN CNA2006800067626A patent/CN101133047A/zh active Pending
- 2006-03-01 EP EP06709928A patent/EP1856094A1/en not_active Withdrawn
- 2006-03-01 BR BRPI0607423A patent/BRPI0607423A2/pt not_active IP Right Cessation
- 2006-03-01 RU RU2007132203/04A patent/RU2007132203A/ru unknown
- 2006-03-01 JP JP2007557577A patent/JP2008531668A/ja active Pending
- 2006-03-01 WO PCT/GB2006/000704 patent/WO2006092579A1/en not_active Ceased
- 2006-03-01 KR KR1020077022388A patent/KR20070107184A/ko not_active Withdrawn
- 2006-03-01 AU AU2006219689A patent/AU2006219689A1/en not_active Abandoned
-
2007
- 2007-08-22 IL IL185453A patent/IL185453A0/en unknown
- 2007-08-27 ZA ZA200707233A patent/ZA200707233B/xx unknown
- 2007-08-29 NO NO20074404A patent/NO20074404L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2600891A1 (en) | 2006-09-08 |
| IL185453A0 (en) | 2008-01-06 |
| WO2006092579A1 (en) | 2006-09-08 |
| JP2008531668A (ja) | 2008-08-14 |
| CN101133047A (zh) | 2008-02-27 |
| GB0504150D0 (en) | 2005-04-06 |
| AU2006219689A2 (en) | 2006-09-08 |
| NZ561246A (en) | 2009-09-25 |
| EP1856094A1 (en) | 2007-11-21 |
| KR20070107184A (ko) | 2007-11-06 |
| MX2007010588A (es) | 2007-10-23 |
| ZA200707233B (en) | 2008-11-26 |
| BRPI0607423A2 (pt) | 2016-11-08 |
| US20100041699A1 (en) | 2010-02-18 |
| AU2006219689A1 (en) | 2006-09-08 |
| RU2007132203A (ru) | 2009-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074404L (no) | Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid | |
| TNSN07325A1 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
| CY1112467T1 (el) | Παραγωγα 1-θειο-d-γλυκιτολης | |
| EA200801381A1 (ru) | Производные пиримидина | |
| TNSN07463A1 (en) | Process for the synthesis of organic compounds | |
| NO20053340D0 (no) | Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1). | |
| CY1111151T1 (el) | Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος | |
| CR9369A (es) | Compuestos de peridil acido acetico | |
| WO2008036967A3 (en) | Novel heterocyclic compounds as lasy activators | |
| NO20070379L (no) | Kjemiske forbindelser | |
| DK1562976T3 (da) | Syntese af estetrol via estron-afledte steroider | |
| MX2009004154A (es) | Purinas como inhibidores de pkc-theta. | |
| NO20070564L (no) | Kinoliner uten tiazolinonsubstituenter. | |
| NO20071254L (no) | Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav. | |
| NO20081621L (no) | Tetrahydrokinoliner, syntese og intermediater | |
| NO20074623L (no) | Fremgangsmate for peptidsyntese | |
| NO20071012L (no) | Fremgangsmate for fremstilling av D-erytro-2,2-difluor-2-deoksy-1-oksoribosederivat | |
| NO20080468L (no) | Diazepinokinoliner, synteser av disse samt intermediater | |
| NO20075618L (no) | Novel compounds as GLP-1 Agonists | |
| EA200701470A1 (ru) | Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений | |
| TW200640912A (en) | Novel processes for the preparation of a 2H-chromene | |
| AR064306A1 (es) | Antagonistas del receptor de angiotensina ii | |
| NO20074259L (no) | Fremgangsmate for fremstilling av substituerte benzoksazolforbindelser | |
| NO20072551L (no) | Fremgangsmate for fremstilling av purinforbindelser | |
| DK1877370T3 (da) | Fremgangsmåde til fremstilling af hydrazon-derivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |